The Tech Race That Could Mint the Next Biotech Giant

Is this the next hot biotech play? ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ [DWR Logo]( December 3, 2024 Hi Reader This $1 trillion tech race is still picking up steam. And some of the biggest players in the space are setting up their next big move. Dupixent, first approved for eczema in 2017, has since expanded to treat several skin conditions. By 2023, it brought in over $11 billion—and its best days may still be ahead. Why? Earlier this year, Dupixent was approved to treat COPD, a lung condition affecting more than 14 million people in the U.S. alone. Experts predict COPD could add another $6 billion in sales for Dupixent over the next decade. That’s fantastic news for Regeneron and Sanofi, the companies behind Dupixent. But for investors, the real story is about the type of drug Dupixent represents—one that’s transforming biotech. These innovative drugs are on track to hit $1 trillion in sales. [Click here to learn more.]( [Read More Button]( Dynamic Wealth Research 2010 West Avenue K #623 Lancaster, California 93536 We are sending this message to {EMAIL}. [UNSUBSCRIBE]( | [PRIVACY POLICY](